Loading…
Iontophoresis mediated in vivo intradermal delivery of terbinafine hydrochloride
The objective of this study was to investigate the use of iontophoresis for the delivery of terbinafine hydrochloride (TH) into hairless rat skin in vivo. Drug formulation was applied to the abdominal skin and studies were performed using anodal iontophoresis. A current density of 250 μA/cm 2 was ap...
Saved in:
Published in: | International journal of pharmaceutics 2010-06, Vol.393 (1), p.113-119 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | The objective of this study was to investigate the use of iontophoresis for the delivery of terbinafine hydrochloride (TH) into hairless rat skin in vivo. Drug formulation was applied to the abdominal skin and studies were performed using anodal iontophoresis. A current density of 250
μA/cm
2 was applied for 10, 15 and 20
min. Tape stripping and skin extraction were performed thereafter. For depot clearance studies, 20
min treatment was followed by tape stripping and skin extraction at 12, 24 and 48
h. Results indicated that iontophoresis delivered significantly more drug into the deeper skin as compared to controls (
p
<
0.05). Drug levels in the stratum corneum (SC) and underlying skin increased with increasing duration of current application. Depot clearance studies suggested drug depletion within 24
h from SC. A redistribution of terbinafine from the SC to the underlying skin over time was observed. Drug was detectable in the underlying skin for at least 48
h suggesting that formation of a drug depot persisted for at least 2 days following iontophoretic treatment. Thus, iontophoresis of TH may be useful in delivering higher drug levels more rapidly into the superficial and deep seated skin infection sites to form a depot providing sustained release. |
---|---|
ISSN: | 0378-5173 1873-3476 |
DOI: | 10.1016/j.ijpharm.2010.04.014 |